Novo Nordisk’s Legal Offensive and Pipeline Pivot: Two Catalysts That Could Reshape the GLP-1 Race
Published on 07/22/2026 at 19:31 | Redaktion boerse-global.de
Novo Nordisk’s stock has clawed back roughly 44 percent from its March nadir of €30.25, trading near €43 in late July. Yet the Danish drugmaker remains 29 percent below last summer’s record high, and the path forward hinges on two high-stakes developments: a freshly filed lawsuit against archrival Eli Lilly and an impending FDA verdict on CagriSema, the next-generation obesity candidate.
The legal salvo landed on July 21 in New Jersey, where Novo accused Lilly of running “malicious and deceptively false” advertisements for Zepbound and Mounjaro. At the heart of the complaint is a claim that Lilly compares its highest approved doses against outdated, weaker semaglutide data from Novo — a tactic the company argues distorts the competitive landscape. A preliminary injunction, if granted in the second half of 2026, could force Lilly to alter its marketing strategy, potentially recalibrating the advertising war in the GLP-1 arena.
That fight unfolds as Novo’s share price remains under pressure. The stock has shed 25 percent over the past twelve months and sits 30 percent below its 52-week peak of €60.95. The 50-day moving average at €40.23 offers near-term technical support, while a breach could open the door to a retest of the year’s lows around €30.25.
Oral Wegovy’s Rocket Start Meets Manufacturing Headwinds
The bull case for Novo rests on a rapidly expanding product cycle. The FDA cleared Wegovy HD — a 7.2-milligram injection — in March 2026, following a Phase 3 STEP-UP study that showed a mean weight loss of 20.7 percent. The European Union followed suit on July 15, approving both the oral Wegovy pill and the single-dose 7.2-mg pen.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
The oral formulation, launched in the U.S. on January 5, has been a standout. By early June, it had surpassed 3 million prescriptions, with roughly 80 percent of patients new to GLP-1 therapy — genuine market expansion rather than brand switching. Novo has invested heavily to meet that demand, opening a $360 million production facility in Bohumil, Czech Republic, in June.
But production remains a vulnerability. The company’s Bloomington, Indiana, plant drew a Form 483 from the FDA in April 2026, citing eight observations including recurring particulate contamination — animal hair among them — and quality system deficiencies. Any escalation in regulatory action there could delay shipments of the high-dose variants critical to countering Lilly’s momentum.
CagriSema: The Next Pivot Point
While the oral Wegovy story is unfolding in real time, the market’s gaze is fixed on CagriSema, Novo’s combination therapy for weight loss. The FDA is reviewing the drug’s approval application, with a decision expected sometime in 2026 — though the company has not specified a date.
The Phase 3 Redefine 1 trial underpins the submission: 91.9 percent of participants achieved at least 5 percent weight reduction, versus 31.5 percent on placebo. A parallel application for type 2 diabetes, based on the Reimagine 1 and Redefine 3 studies, remains in early discussions with regulators — no formal filing has been made.
A green light for CagriSema would give Novo a second flagship obesity drug just as Eli Lilly’s competitive pressure intensifies. It would also validate the broader pipeline strategy. Chief Scientific Officer Martin Lange has pointed to amylin-based candidates like Zenagamtide — a GLP-1/amylin injectable combination now in mid-stage trials — as evidence that Novo is building beyond semaglutide alone.
Structural Pressures and Cost Discipline
Even if the pipeline delivers, Novo faces structural headwinds. Starting in 2027, the U.S. Inflation Reduction Act will impose Medicare price caps on blockbusters including Ozempic. To offset that drag, the company is executing a global restructuring that will cut 9,000 jobs and aims to save 8 billion Danish kroner annually by the end of 2026.
The cost-cutting underscores how much margin pressure has built. Novo’s own guidance calls for a 4 to 12 percent decline in full-year adjusted revenue — a sobering forecast for a company that dominated the GLP-1 narrative just eighteen months ago.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
Three Dates That Will Decide the Second Half
Investors are now triangulating between three potential catalysts. The commercial launch of the 7.2-mg Wegovy pen in the EU, following the July 15 approval, is slated for the third quarter. The restructuring program is scheduled to conclude by year-end. And the preliminary injunction ruling in the Lilly lawsuit could come at any point in the second half, potentially reshaping the advertising battle before the next wave of competition arrives.
The stock’s technical setup offers a split verdict. At €43.49, Novo trades 8.3 percent above its 50-day moving average and 7.6 percent above the 200-day line. The relative strength index sits at 59.2 — suggesting buying pressure is building without reaching overbought territory. But with annualized 30-day volatility at 25.5 percent, swings around any CagriSema news or regulatory update are likely to be sharp.
For now, the oral Wegovy script count is the most tangible bullish signal. Whether it can sustain momentum long enough for CagriSema to arrive — and for the Lilly lawsuit to tilt the competitive balance — will determine whether Novo’s recovery has legs or remains a dead-cat bounce in a market that has already moved on.
Ad
Novo Nordisk Stock: New Analysis - 22 July
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
